LAB (Standard BioTools Inc.) Stock Financials & Earnings

LABStandard BioTools Inc.

Mkt Cap$388M

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$85M

Net Income (TTM)-$75M

EPS (TTM)-$0.20

Free Cash Flow (TTM)-$83M

Gross Margin49.9%

Op. Margin-109.3%

Net Margin-87.8%

FCF Margin-96.9%

P/S Ratio (TTM)4.6x

P/E Ratio (TTM)—

YoY Rev Growth-46.6%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$25M	$12M	-$17M
Q2 23	$28M	$14M	-$17M
Q3 23	$25M	$11M	-$21M
Q4 23	$28M	$13M	-$21M
Q1 24	$46M	$24M	-$60M
Q2 24	$22M	$10M	-$30M
Q3 24	$45M	$23M	-$32M
Q4 24	$47M	$22M	-$33M
Q1 25	$41M	$20M	-$33M
Q2 25	$22M	$11M	-$26M
Q3 25	$20M	$9M	-$23M
Q4 25	$3M	$3M	-$11M

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter

Revenue by Geography

Quarter	Americas	Asia Pacific	Emea
Q1 23	$12M	$6M	$8M
Q2 23	$10M	$6M	$11M
Q3 23	$11M	$6M	$8M
Q4 23	$13M	$6M	$9M
Q1 24	$25M	$8M	$13M
Q3 24	$24M	$5M	$16M
Q1 25	$19M	$9M	$13M
Q2 25	$9M	$4M	$9M
Q3 25	$8M	$4M	$7M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$114M	$41M	$155M
Q2 23	$142M	$0	$142M
Q3 23	$80M	$49M	$129M
Q4 23	$52M	$63M	$115M
Q1 24	$287M	$175M	$462M
Q2 24	$270M	$125M	$395M
Q3 24	$211M	$156M	$366M
Q4 24	$167M	$126M	$293M
Q1 25	$151M	$107M	$258M
Q2 25	$159M	$78M	$237M
Q3 25	$129M	$65M	$195M
Q4 25	$118M	$69M	$188M

Shares Outstanding

Revenue Per Employee

Revenue / Employee